Bitwise: Ethereum is like the 'Microsoft' in the memory blockchain, ETH's performance may improve by the end of the year
According to CoinDesk, cryptocurrency management company Bitwise stated in a report on Tuesday that Ethereum (ETH) seems to be less popular now, but its underperformance may reverse before the end of the year.
Bitwise pointed out that the price of Ethereum has not changed much since the beginning of the year, while Bitcoin (BTC) has risen by 38% and Solana's SOL has risen by 31%. The report states that the recent underperformance of Ethereum is due to risks related to the November US presidential election, increasing competition from Solana and other memory blockchains, a challenged token economy, and mixed reactions from the launch of US Ethereum spot exchange traded funds (ETFs).
However, the situation is not entirely pessimistic. Bitwise points out that the majority of stablecoins are issued on Ethereum, with over 60% of decentralized financial (DeFi) assets locked onto this blockchain, and the popular prediction market Polymarket also settles on this Layer 1 chain. Bitwise investment gains, Matt Hougan wrote:
Ethereum has the most active developers, active users, and a market value five times larger than its closest competitors
Hougan also stated that Ethereum is "like Microsoft in a memory blockchain," and everyone wants to talk about newer companies and their game changing technologies such as Google, Slack, and Zoom, "but Microsoft is still bigger than them combined.
The Bitwise report states that the challenge of Ethereum is not "life or death" and the market may re evaluate the cryptocurrency as the US election approaches, stating that "it looks like a potential reverse bet before the end of the year".
相关文章:
- 遭骇 2.6 亿美金后冻结链上交易,Sui「链上审查」引中心化质疑
- meme币交易所下载安卓最新 meme币最新版手机app下载
- Farcaster生态新动态:品牌重塑、Pro订阅与多链集成引领未来
- 芝麻交易所ouyi加密货币钱包在线下载-芝麻交易所web3钱包免费版v6.3.7安装地址
- gec数字币价格-gec数字货币的最新价位
- 易欧意okx易所电脑版下载与安装指南
- rose数字货币价格-数字货币gram价格
- 共享经济概念31日主力净流出1.41亿元,力帆科技、移为通信居前
- 以太坊市值超越美国银行,5月底ETH能否重回3000美元?
- 阳光诺和:自研立项1类创新药项目共12项,STC007注射液已进入临床二期